Prenylated p-Coumaric Acid Derivatives Mitigate Neurobehavioral and Neuroinflammatory Alterations Associated with Experimental Colitis.

What To Know

The study used dextran sulfate sodium (DSS) to induce colitis in mice and treated them with Artepillin C, Baccharin, or Drupanin given orally at several doses.

Researchers assessed clinical colon measures, histology, behavioral tests (open field, novel object recognition, elevated plus maze, tail suspension), and biochemical markers in colon, serum, cortex, and hippocampus.

The authors report that higher doses of the compounds reduced colonic damage, improved recognition memory, and reduced anxiety- and depressive‑like behaviors in mice, alongside changes in antioxidant defenses and lower lipid peroxidation and inflammatory markers.

These findings are preclinical and describe biological effects in an animal model, not results from human studies. The study highlights preclinical potential for these compounds to affect both intestinal inflammation and neurobehavioral changes linked to colitis, but it does not provide evidence that they are safe or effective in people with IBD.